Related Experiment Videos
Therapeutic vaccination in chronic hepatitis B
Hakan Senturk1, Fehmi Tabak, Meral Akdogan
1Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey. haksen@escortnet.com
Journal of Gastroenterology and Hepatology
|March 16, 2002
Summary
Genhevac-B vaccine shows promise in reducing HBV-DNA levels for chronic hepatitis B patients. Combining Genhevac-B with interferon-alpha may improve sustained response rates.
Area of Science:
- Hepatology
- Immunology
- Vaccinology
Background:
- Chronic hepatitis B (CHB) remains a significant global health concern.
- Current treatments for CHB have limitations in achieving sustained viral clearance.
- Novel therapeutic strategies are needed to improve outcomes for CHB patients.
Purpose of the Study:
- To evaluate the efficacy of a pre-S2-containing vaccine, Genhevac-B, in patients with chronic hepatitis B.
- To compare the effectiveness of Genhevac-B monotherapy versus a combination therapy with interferon-alpha-2b.
Main Methods:
- A total of 25 treatment-naive CHB patients received escalating doses of Genhevac-B.
- Patients with detectable HBV-DNA after initial vaccination were randomized to receive either Genhevac-B or interferon-alpha-2b.
- Response was defined as loss of HBV-DNA and normalization of ALT levels.
Main Results:
- Genhevac-B demonstrated a reduction in serum HBV-DNA levels in most CHB patients.
- Sustained response rates were 46% for the vaccine-only group and 50% for the combination group.
- Histological improvement was observed in a majority of responders and some non-responders.
Conclusions:
- Genhevac-B is effective in decreasing HBV-DNA levels and achieving sustained clearance in some CHB patients.
- Combination therapy with Genhevac-B and interferon-alpha-2b appears more effective than interferon-alpha-2b alone, particularly for vaccine failures.
- Further research is needed to elucidate the mechanism of action for this combination therapy.